ALNY Quantitative Stock Analysis

According to Validea's guru fundamental report, Alnylam Pharmaceuticals receives a 94% rating based on their Twin Momentum Investor model, which is based on the strategy of Dashan Huang and combines fundamental and price momentum; a score above 90% typically indicates strong interest. The model uses seven fundamental variables to identify companies in the top 20% that are likely to outperform the market, and combining this measure with price momentum doubles the potential outperformance.

Analysis

Alnylam Pharmaceuticals, Inc. (ALNY), a large-cap stock in the Biotechnology & Drugs industry, has received a notably high rating of 94% from Validea's Twin Momentum Investor model. This model, based on Dashan Huang's published strategy, emphasizes a combination of fundamental momentum and price momentum, with scores above 90% typically indicating strong interest. ALNY successfully passed all key tests within this strategy, including 'FUNDAMENTAL MOMENTUM', 'TWELVE MINUS ONE MOMENTUM', and 'FINAL RANK'. Huang's methodology identifies seven fundamental variables—earnings, return on equity, return on assets, accrual operating profitability to equity, cash operating profitability to assets, gross profit to assets, and net payout ratio—to form a single fundamental momentum measure. Stocks ranking in the top 20% by this measure historically outperformed the market, an effect reportedly doubled when combined with price momentum. The overall sentiment surrounding this report is strongly positive (0.85), with ALNY's specific sentiment score at an even higher 0.9, suggesting a favorable quantitative assessment based on these momentum factors.

Key Decisions for Investors

• Investors employing momentum-based strategies should consider ALNY as a candidate for further investigation, given its high score on a recognized twin momentum model and positive signals in both fundamental and price momentum.
• It would be prudent to monitor the seven specific fundamental variables highlighted by Dashan Huang's model (earnings, ROE, ROA, etc.) for ALNY to track continued alignment with the strategy's outperformance criteria.
• While the model's assessment is strong, investors should integrate this quantitative signal with their qualitative due diligence, overall market outlook, and specific risk appetite for the biotechnology sector before making investment decisions.